Biomedical Publisher Future Science Group Joins Taylor & Francis

Taylor & Francis’ Support for Scientific and Medical Communities Expanded with Journals, Digital Hubs and Publishing Solutions

Knowledge services provider Taylor & Francis has today announced the addition of Future Science Group (FSG), publisher of medical, biotechnological and scientific research. As well as bringing a portfolio of cutting-edge journals and digital hubs, FSG’s leading publishing solutions program will enable Taylor & Francis to offer researchers and medical communication planners a host of additional services.

Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs. These complement the existing range of over 340 Taylor & Francis medical and healthcare journals, including the Expert Collection, which is the world's largest series of review journals in research, development and clinical medicine.

FSG publications represent many of the most important and fast-growing fields of scientific, medical and pharmaceutical research, including oncology, medicinal chemistry, immunotherapy, microbiology, nanomedicine and biotechnology. Researchers can choose to publish open access (OA) in all FSG journals, with 15 titles fully OA.

The addition of FSG will also accelerate the growth of Taylor & Francis services for researchers and medical communication planners. FSG’s market-leading Plain Language Summary Hub supports authors to make technical content accessible for lay audiences and empowers patients in decision-making about their care.

Leon Heward-Mills, Researcher Services Managing Director at Taylor & Francis, said: “We’ve long respected the work of FSG’s creative and plain-language summary teams. Their expertise will help us scale up our existing researcher services programs, deepen our relationships with customers, and support real-world impact.”

James Drake, Founder and Chairman of Future Science Group, said: “Over the last 22 years, FSG has developed a range of unique offerings, all underpinned by a mission to convene scientific communities, and support translation, collaboration and innovation. These are priorities I know the team at Taylor & Francis value too. I’m certain that the move we’re announcing today will ensure the FSG journals, hubs and services reach their full potential and continue to meet the evolving needs of today’s researchers.”

Liz Knowles, Global Portfolio Director for Medicine at Taylor & Francis added, “The FSG journals and hubs are a perfect fit for Taylor & Francis, complementing our existing areas of strength as well as supporting growth in many of the fields we had identified for extra investment. We’re looking forward to working with our new colleagues to increase the reach and impact of FSG publications with research communities across the globe.”